VSS buys Advanstar in $1.1 billion deal

Share this article:
Advanstar is being acquired by private equity firm Veronis Suhler Stevenson (VSS), co-owner of Ascend Media and a controlling investor in MediZine, in a $1.1 billion deal. Advanstar, whose life sciences titles include Medical Economics, Patient Care, Drug Topics and Pharmaceutical Executive, is being sold by DLJ Merchant Banking Partners/Credit Suisse First Boston, which picked up the firm in 2000. In addition to life sciences, the firm boasts verticals in fashion and powersports, as well as apparel show MAGIC Marketplace and powersports show Dealer Expo. VSS acquired a controlling stake in Healthy Living publisher MediZine earlier in March and co-owns Ascend Media, another major medical publisher, with JP Morgan Partners. The firm sold its stake in healthcare information products company Solucient to Thomson last year and offloaded medical manufacturing trade publisher Canon on Apprise Media in 2005.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...